DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
N/A
The DRAGON registry aims to collect data on combined portal and hepatic vei...
Status
Recruiting
Location
Rush University Medical Center
Start Date
2021-03-16
Trial ID
NCT07717437
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
PHASE2
This phase IIb trial tests the effect of HRX215 in treating patients with c...